장기간 생식샘 자극 호르몬 방출 호르몬 작용제 치료를 하는 심각한 자궁내막증 환자에서 랄록시펜의 투여

Abstract

Abstract OBJECTIVE: To evaluate the efficacy of raloxifene in preventing bone loss associated with long term GnRH-a administration. DESIGN: A prospective, randomized, observational follow-up study. SETTING: Obstetrics and Gynecology department in a Chosun University Hospital, Korea. MAIN OUTCOME MEASURE(S): Bone mineral density(BMD) changes in both groups. METHODS: Twenty-two premenopausal women with severe endometriosis were treated with leuprolide acetate depot at a dosage of 3.75 mg/4weeks for 48 weeks. BMD was evaluated at admission and after 12 treatment cycles. RESULTS: At cycle 12 of GnRH-a plus raloxifene treatment, lumbar spine, trochanter, femoral neck, and ward’s BMD differed from before the treatment. The lumbar spine and trochanter decreased slightly 1 year after treatment(Table 2), but were not significantly different. CONCLUSIONS: Our study shows that the administration of GnRH-a plus raloxifene in pre-menopausal women with severe endometriosis is an effective long-term treatment to prevent bone loss. Key words: Long-term GnRH agonist / raloxifene / severe endometriosis / bone mineral density(BMD)